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Abstract Air pollution constitutes an important factor for asthma aggravation, and there is increased concern about
respiratory health effects of common air pollutants.The purpose of this study was to examine how exposure to a high
ambient concentration nitrogen dioxide (NO2) prior to a bronchial allergen challenge modulated the inflammatory re-
sponse in the bronchi. Thirteen subjects with mild asthma and allergy were exposed at rest to either purified air or
500 mgm3 NO2 for 30min, followed 4 h later by an allergen inhalation challenge.The exposures (NO2 or air) were
performed in randomorder and at least 4 weeks apart.Lung function during NO2/air exposure and allergen challenge
wasmeasuredbyplethysmography, andthenhourlybyportable spirometryafterexposures.Subjective symptomswere
recorded during and after exposure.Bronchoscopy with bronchial wash (BW) and bronchoalveolar lavage (BAL) was
performed 19 h after allergen challenge.NO2+allergen enhanced the percentage of neutrophils in both BWand BAL
comparedto air+allergen (BW19 vs.11,P¼0.05;BAL 3 vs.1,P¼0.02medianvalues).Thelevelsofeosinophilcationicprotein
(ECP) in BWwashigherafterNO2+allergencomparedto air+allergen (9.0 vs.3.6 mg/l;P¼0.02,medianvalues).Therewas
noNO2-associated effecton symptomsorpulmonary function.These data suggestthat ambient NO2 can enhance aller-
gic inflammatory reaction in the airwayswithout causing symptoms or pulmonary dysfunction.r 2002 Published by Elsevier
Science Ltd
Available online athttp://www.sciencedirect.com
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markers.INTRODUCTION
Nitrogen dioxide (NO2), a gas produced by combustion,
is a common environmental air pollutant.The main out-
door sources are vehicular tra⁄c, and indoor sources
are gas appliances.
Individuals with asthma aremore sensitive to NO2 ex-
posure than healthy subjects, according to results fromReceived 6 July 2001, accepted in revised form10 April 2002
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E-mail: charlotte.barck@medhs.ki.secontrolled human-exposure studies. Short exposures to
high ambient levels ofNO
2
can increase exercise-induced
bronchospasm (1) and thebronchial responsiveness to in-
haled nonspeci¢c agents in asthmatics (2). The main ef-
fect of NO2 in these studies was on bronchial
responsiveness, with pulmonary function not being af-
fected at those NO2 doses.
NO2 can also enhance the asthmatic response to in-
haled allergen (3,4). This amplifying e¡ect on the
asthmatic response has also been reported after
repeated exposure to NO2 in combination with low,
non symptom-causing doses of allergen (5), suggesting
that NO2 may exert this e¡ect commonly on asthma
patients.
908 RESPIRATORYMEDICINEThe mechanisms for NO2’s enhancing e¡ect on the
asthmatic reaction to allergen appear to be related to
an increased in£ammatory reaction in the bronchi.
The extent to which in£ammatory cells and mediators
are linked to this response is not well understood.
Exposure to high doses of NO2 alone (3000^
7000mgm3), which occurs in certain industries
and mines, has been shown to increase the number
of neutrophils in bronchial lavage £uid in healthy
subjects the ¢rst hours after exposure (6^8), while ex-
posure to ambient levels of NO2 (o1000mgm3) does
not seem to a¡ect cell numbers in bronchial lavage £uid
in humans (6).
Bronchial allergen challenge, on the other hand, gives
an in£ammatory response which is characterized in
bronchoalvedar lavage (BAL) £uid by eosinophilia, which
is noted as soon as 2^4h after challenge and persisting
up to 24h post-challenge (9). Occasionally, neutrophilia
occurs in the bronchi some hours after allergen chal-
lenge, but this usually subsides with normal values noted
24h later (9).
These results suggest that the neutrophil and eosino-
phil constitute the prime e¡ector cells in NO2 and aller-
gen-induced airway in£ammatory reaction. However, to
date there has been no experimental examination
of the impact of a combination of NO2 and allergenTABLE 1. Anthropometric and clinical data
Subject Sex Age
(year)
Smoking Asthma
duration
(year)
Allergen
inhaled
FE
inclu
1 M 39 E 25 B
2 F 23 N 6 T
3 M 30 E 4 T
4 F 23 E 3 B
5 M 30 N 26 B
6 F 25 N 20 T
7 M 33 N 22 B
8 M 27 N 25 B
9 F 25 N 22 T
10 M 32 E 12 B
11 F 25 N 8 T
12 F 26 N 1 T
13 F 27 N 8 T
Mean 28 14
Std 5 10
Median
25th percentile
75th percentile
Note:F¼female,M¼male;N¼never smoker,E¼ex smoker;T¼
wProvocative dose of histamine causinga100% increase in speci
zProvocative dose of allergen causing a100% increase in speci¢c
}Inhaled allergen dose after NO2/air.on the in£ammatory response in the bronchi, though
combinationNO2 and allergen exposure is likely to occur
in asthma patients.
Wehypothesized thatNO2would enhance the airway
in£ammatory response of eosinophil and neutrophil
granulocytes andmast cells to allergen inhalation.
We aimed to test this hypothesis in an exposure study,
with short-term exposure to NO2 and a subsequent al-
lergen challenge.
METHODS
Subjects (Table1)
Thirteen adult subjects with mild asthma and allergy to
birch or timothy pollen participated in the study. There
were six men and seven women; the mean age was 29
years in the agerange 23^39 years. Allwerenonsmokers.
At a pre-inclusion visit at least 4 weeks before the
study started, a seasonal allergy to either birch or ti-
mothy pollen was con¢rmed by positive skin prick test
(43mm). The diagnosis of extrinsic asthma was based
on a typical history of attacks of dyspnoea during the
pollen season and a positive bronchial challenge with
the relevant allergen. Six subjects had a late phase reac-
tion de¢ned as =15% decline in forced expiratory volumeV1at
sion (l)
FEV1at
inclusion
(% pred)
Skin
prick
test*
(mm)
Hista-
mine
PDSRaw100%
w
(SQunits)
Allergen
PDSRaw
100%z
(SQunits)
Allergen
dose}
(SQunits)
3.75 86 6.5 129 6654 1980
3.16 85 7.5 172 1474 660
4.08 106 4.5 530 1097 440
3.61 119 7 478 2194 880
4.12 85 10.5 402 231 96
3.87 100 9 521 23 10
3.91 87 8 128 326 138
4.5 103 12 109 34 14
3.41 97 8.5 100 39 17
4.2 103 14 284 256 110
3.03 88 12 803 423 220
3.09 91 8 326 55 19
4 109 14 699 163 69
3.75 97
0.46 11
9 326 256 110
129 47 18
526 1286 550
timothy,B¼birch.*Skinprick testo3mm¼positive reaction.
¢c airwayresistance.
airwayresistance.
NO2EFFECTS INASTHMATICSAFTER ALLERGENCHALLENGE 909in 1s (FEV1) 3^10h after the allergen challenge. Airway
hyperresponsiveness was also con¢rmed by a positive
histamine inhalation test. Upon inclusion, the lung
function expressed as FEV1 was 97711% of predicted
(mean7SD; range 85^119%). All subjects were
treated with inhaled b2-agonist as needed, and
12 subjects were treated with inhaled steroids only
during the pollen season, though none during the study
period.
All subjects had a normal serum CRP-value on the
¢rst exposure day as an indication of no ongoing bacter-
ial infection.
The study was approved by the Ethics Committee at
Huddinge University Hospital.
Study design
All subjects were exposed for 30min at rest in an expo-
sure chamber to ¢ltered air or to a concentration of
500mgm3 (260ppb) NO2 on two separate occasions
at least 4weeks apart.The orderof exposurewasrando-
mized (7 ¢rst NO2, 6 ¢rst air). Four hours after expo-
sure, a bronchial challenge with an individually ¢xed
dose of birch or timothypollenwasperformed.The time
interval of 4 hwasbased on an establishedprotocol from
previous studies (4).The inhaled allergen dosewas 40%of
the dose estimated to cause100% increase in speci¢c air-
wayresistance at the screening visit, based on a previous
study with NO2 and allergen from our laboratory (5).
Bronchoscopy withbronchialwash (BW) andbronchoal-
veolar lavage (BAL) was performed 19h after the aller-
gen challenge.
Each experimenthad the followingdesign: after arrival
to the laboratory in the morning, the subject rested for
15min. Speci¢c airwayresistance (SRaw) and thoracic gas
volume (TGV) were measured with a whole-body
plethysmograph, and FEV1 with a portable spirometer.
The subject then rested 10min more before entering
the exposure chamber. During the 30min of
exposure to air/NO2, lung function (SRaw, TGV) was
measured after 4, 15, and 30min of exposure, and
an interview concerning symptoms was conducted
after 3 and 26min according to a standardized question-
naire.
After exposure, FEV1 was measured hourly using a
portable spirometer. Before and after the allergen inha-
lation, lung function was again measured by plethysmo-
graphy. After the allergen inhalation, the subject went
home and continued tomeasure FEV1hourly until10p.m.
The subjects were instructed to use an inhaled
bronchodilator if necessary and to keep a record of
symptoms andmedication.
The exposure types were blinded to the subjects and
the investigators analysing the bronchial lavage £uid and
the results from the portable computerized spirometer.Whole-body plethysmography
Airway resistance (SRaw) and TGV were measured in a
constant volume body plethysmograph (Model 2000
TB; Cardio-pulmonary Instruments, Houston, TX,
U.S.A.) according to the method of Du Bois and collea-
gues (10,11).
The gas £ow/box-pressure slopes were measured be-
tween gas £ow +0.5 and 0.5 l s1 (expiration i^n-
spiration) as a mean of two or three measured slopes.
The mouth/box-pressure slopes were measured be-
tween the endpoints, again as the mean of two to three
curves.
Spirometry
The measurements of FEV1were made using a portable
computerized spirometer (Diary Card spirometer, Mi-
cromedical Ltd.Chatham, Kent, U.K.) and the data later
downloaded to a computer.
Themaximal fall in FEV1frombefore allergenchallenge
to 3^10h after allergen challenge, as well as the average
fall in FEV1 during this period, was used to measure the
asthmatic reaction during the late phase.
Results for FEV1 are provided in litres, and statistical
evaluation of e¡ects are normalized to each individual’s
best FEV1.
Histamine bronchial challenge
Histamineprovocation testswereperformedbyusing an
automatic inhalation-synchronized dosimeter jet nebuli-
zer (Spira Elektro 2; Respiratory Care Center, Hameen-
linna, Finland) with an adjustable aerosol delivery time
according to a previously described method (5,12). SRaw
and TGVweremeasured 3min after each dose.The pro-
vocative dose (PDSRaw 100%) was calculated by linear in-
terpolation on a logarithmic scale.
Allergen bronchial challenge
The allergen challenge at the screening visit and during
the study was performed with the same dosimeter jet
nebulizer (Spira Elektro 2) as for histamine inhalation.
Standardized and freeze-dried birch or timothy allergen
extracts (Aquagen,Alk,Copenhagen,Denmark)weredi-
luted and used at a maximum of four concentrations:
1000, 4000, 16 000 and 64 000 (Standardized Quality)
SQ allergen unitsml1.The nebulizer was set to nebulize
for 0.5 s giving an output of 7.1mlbreath1. At each con-
centration, two and four breaths could be taken, and if
needed even followedby eight and16 breaths at the high-
est concentration providing doses from14 to 7040SQ al-
lergen units. SRaw and TGV were measured15min after
each dose of allergen. The challenge proceeded until a
100% increase in SRaw was reached. PDSRaw 100% for
910 RESPIRATORYMEDICINEallergen was calculated by linear interpolation on a loga-
rithmic scale.
The inhaled allergen dose in the study was set to 40%
of the PDSRaw 100% at the screening visit, or, when this
was impossible to administer for practical reasons, the
dose was as above (seeTable 1). FEV1 and SRaw were re-
corded immediately before and 15min after the single
dose of allergenwas inhaled.
Blood samples
Blood samples were obtained on two occasions; 1 day
prior to exposure for CRP analyses and 1 day prior to
BAL for analysis of albumin.
Questionnaire
After 3 and 26min of exposure in the chamber, the sub-
jects were asked 16 questions concerning respiratory
symptoms and perceptions of discomfort (i.e. tight
chest, cough, headache, odour), reporting symptoms on
a scale of 0 (none)^7 (maximal).
Throughout the day, and then on the following morn-
ing, the subjects kept a self-administered daily record of
bronchodilator medication and symptoms from bronchi,
nose, and eyes.
Gas dilution and exposure system
NO2 from a gas bottle (Alfax, approximately
8.000mgm3 NO2) was diluted in two steps to a ¢nal
concentration of approximately 500mgm3 NO2 and
then was fed into the exposure chamber (volume
7m3). The gas dilution and exposure system is pre-
sented in detail elsewhere (13).
Chemical analyses
NO2 concentrations in the exposure chamber were
measured with a chemiluminescence instrument (Model
8440 Nitrogen Oxides Analyser; Monitor Laboratories,
Englewood,CO,U.S.A.).For calibration, anNO2permea-
tion tube and NO calibration gas (Model 8500 Calibra-
tor; Monitor Laboratories, Englewood, CO, U.S.A.;
AGA Special gas, 100ppmNO) was used. A calibration
procedurewas performed daily.
The subjects’ individual exposure to NO2 outside the
chamber during the studydayswasmeasuredwith aper-
sonal passive (¢lter badge) sampler (Toyo Roshi Kaisha,
Ltd,Tokyo, Japan) (14).
Exposure data
NO2 concentrations in the exposure chamber were
measured in the breathing zone of the subject. Theconcentration was 493710; 468^505mgm3 (average
of mean concentrations during 30min7SD; range). Dur-
ing exposure to ¢ltered air, the NO2 concentration was
below 10mgm3. The temperature in the exposure
chamber was 24.070.81C (mean7SD) during air and
24.470.81C during NO2 exposure. The corresponding
values for relative humidity were 39712% (n¼11) and
3678% (n¼12).The exposure to NO2 in ambient air out-
side the chamber measured with the personal sampler
was1879mgm3 (23hmean7SD, 9 a.m. day1^8 a.m.
day 2) during the NO2 exposure and 25711mgm3
during the air exposure, whichwas signi¢cantly di¡erent
(P¼0.046).
Bronchoscopy andbronchoalveolar lavage
All bronchoscopies were done between 8 and 9 a.m. by
the same bronchoscopist (CB).VC and FEV1were mea-
sured before the procedure. Fibreoptic bronchoscopy
was performed after premedication with morphine hy-
drochloride and scopolamine hydrobromide (Mor¢n-
scopolaminsPharmacia, Uppsala, Sweden). Fifteen min-
utes before the bronchoscopy, all subjects inhaled
0.4mg salbutamol. Local anaesthesia was administered
before and during the procedure with lidocaine (Xylo-
cains, Astra, S˛dertUlje, Sweden). The Olympus B1-IT
20 (Olympus Optical Company, Tokyo, Japan) broncho-
scope was introduced through the nose or the mouth
into the lung, and wedged in a subsegmental bronchus
of the middle lobe. Lavage was performed using one ali-
quot of 20ml, and three aliquots of 50ml sterile warm
0.9% NaCl, instilled into the middle lobe subsegment.
The £uidwas gently aspirated after each aliquot and col-
lected in propylene tubes. The ¢rst 20ml that was in-
stilled, the BW, was collected separately from the
remaining150ml, the BAL.
Sample processing
The lavage £uidwas ¢ltered through a Dacron net (Milli-
pore, Cork, Ireland). Cells were pelleted by centrifuga-
tion at 41C, 400g for10min, and the supernatants were
stored at 701C after an additional centrifugation at
41C, 600g for10min.
The cell pellets were resuspended in Hepes bu¡er
(RPMI).The total number of cells was counted in a Bˇr-
ker chamber, and their viability was tested by the exclu-
sion of trypane blue. Slides for di¡erential counts were
preparedbycytocentrifugation at 500 rpm for 3min (Cy-
tospin 3 Shandon, Southern Products Ltd., and Runcorn,
England). Slideswere stainedwith May-Grˇnwald Giem-
sa, and 500 cells were counted. Mast cells were stained
with acid toluidine blue and counterstained with MayerŁ s
acid haematoxylin.
NO2EFFECTS INASTHMATICSAFTER ALLERGENCHALLENGE 911Analyses of solublemediators
Analyses of soluble mediators were performed in cell
free BW and BAL £uids .The £uids were distributed in
portions and stored at701Cuntil analysed.
ECP levels weremeasuredwith a £uoroimmunoassay,
Pharmacia ECP Cap System FEIA, (Pharmacia & Upjohn,
Uppsala, Sweden), with a detection limito2 mg/l.
MPO levels were measured with a competitive RIA
(Pharmacia & Upjohn), which had a detection limit of
o8mgml1. In this assay, MPO competes with a ¢xed
amount of 125I labelled MPO for the binding sites of spe-
ci¢c antibodies.
The levels of human IL-5, IL-8, eotaxin, and soluble-
ICAM-1weremeasuredby ELISA technique using Quan-
tikine immunoassays (R&D Systems, Inc, Minneapolis,
MN, U.S.A.). According to the manufacturer, the mini-
mum detectable concentrations for substances were IL-
5 3.0pg/ml, eotaxin 5.0pgml1, IL-8 10pgml1, and s-
ICAM-10.35ngml1.
Statistics
Data obtained forNO2 and ¢ltered air were analysed for
di¡erences using the nonparametric Wilcoxon signed
rank test.
The statistical program used was SPSS for PowerMa-
cintosh (SPSS Inc.Chicago, IL, U.S.A.). Probability values
ofo5% were considered signi¢cant.
Pair-wise correlations of delta values were calculated
for r values (Pearsons correlation coe⁄cient) with JMPs
version 3.2.2 statistical software from SAS Institute Inc.
RESULTS
Speci¢c airway resistance (SRaw), and
thoracic gas volume (TGV) (Table 2)
SRaw was signi¢cantly higher at baseline on the NO2 ex-
posure day [4.0 cmH2O s
1 (3.04^6.02) NO2 vs. 3.69
(2.88^4.89) air, P¼0.04].TABLE 2. SRaw and TGV
Air
SRaw (cmH2O s
1)
Before expo 3.69 (2.88^4.89)
After expo 3.85 (2.83^5.82)
Before allergen 5.33 (4.74^5.84)
After allergen 6.50 (4.91^8.48)
TGV (l)
Before expo 3.28 (2.88^3.54)
After expo 3.23 (2.87^3.71)
Before allergen 3.30 (2.87^3.56)
After allergen 3.59 (2.84^4.22)
Data presented asmedian and interquartile range, n¼13.*WiThere were no signi¢cant di¡erences in SRaw orTGV
between air and NO2 during exposure in the chamber
or immediately after bronchial allergen challenge.
Forced expiratory volume in1s (FEV1)
(Table 3)
FEV1 in litres before NO2 and control exposure were si-
milar (3.6870.45 and 3.6570.48 mean7SD, respec-
tively) and before allergen provocation (3.6770.44 and
3.6770.48, respectively). The allergen provocation in-
duced a small but (for group averages) statistically signi¢-
cant decrease in FEV1 during the early phase of 4%
(0.1570.19; P¼0.011) in the NO2 group and 5%
(0.2070.32; P¼0.013) in the control. FEV1, averaged over
the 3^10h after allergen challenge, was 7% (0.2670.28;
P¼0.006) for the NO2 group and 8% (0.2870.33;
P¼0.009) for the control group lower than immediately
before allergen challenge. The maximal fall during late
phase was13% (0.4970.43; P¼0.002) for the NO2 group
and 15% (0.5570.51; P¼0.004) for the control group.
There were no tendencies towards di¡erences in e¡ect
between NO2+allergen and control+allergen exposure
during the early or late phase (P40.42). Six in the air+-
allergen group and ¢ve in the NO2+allergen group had a
late FEV1reaction greater than15%.
Subjective complaints
When the subjects were interviewed during exposure
concerning subjective complaints, no di¡erencebetween
air and NO2 exposure could be detected except for a
slight increase in sense of anxiety and odour after 4min
of exposure to NO2 [mean 1.1 vs. 2.1, P¼0.03 (anxiety),
and 1.4 vs. 2.1, P¼0.05 (odour) on a scale in the range 1^
7].These e¡ects had vanished after 28min of exposure.
After exposures, subjective symptoms andmedication
did not di¡er signi¢cantly between air+allergen and
NO2+allergen.NO2 P-value*
4.00 (3.04^6.02) 0.04
4.32 (2.89^5.52) n.s.
4.92 (4.45^5.69) n.s.
6.23 (5.58^8.85) n.s.
3.52 (2.96^3.89) n.s.
3.53 (2.91^4.09) n.s.
3.36 (2.93^3.87) n.s.
3.36 (3.02^4.03) n.s.
lcoxon’s nonparametric signedrank test; n.s.¼nonsigni¢cant.
TABLE 3. Air/allergen vs.NO2/allergen (FEV1*)
Subject Air/allergen NO2/allergen
Pre-
expo
Pre-
allergen
Earlyw
phase
Early
phase
% change
Late
phasez
(mean)
Late
phase
(mean)
% change
Late
phase
(min)
Late
phase
(min)
% change
Pre-
expo
Pre-
allergen
Early*
phase
Early
phase% change
Late
phasew
(mean)
Late
phase
(mean) %
change
Late
phase
(min)
Late
phase
(min)
% change
1 3.96 3.91 3.50 10 3.97 2 3.91 0 3.82 3.68 3.85 5 3.86 5 3.71 1
2 3.10 3.21 3.03 6 2.73 15 2.37 26 3.16 3.12 3.03 3 3.00 4 2.87 8
3 4.11 4.15 3.82 8 3.85 7 3.75 10 4.14 4.12 3.93 5 3.71 10 3.47 16
4 3.54 3.64 2.46 32 2.58 29 2.11 42 3.50 3.41 3.03 11 2.73 20 2.16 37
5 4.13 4.12 4.15 1 3.62 12 3.25 21 3.91 3.95 3.91 1 3.48 12 2.95 25
6 3.67 3.78 3.66 3 3.67 3 3.58 5 3.87 3.92 3.71 5 3.29 16 3.12 20
7 3.43 3.41 3.36 1 2.82 17 2.54 26 3.77 3.85 3.66 5 3.15 18 2.66 31
8 4.38 4.43 4.37 1 4.28 3 4.23 5 4.41 4.40 4.43 1 4.38 ,45 4.34 1
9 3.28 3.36 3.18 5 3.22 4 3.11 7 3.31 3.28 3.18 3 3.23 2 3.14 4
10 3.97 3.85 3.71 4 3.67 5 3.12 19 3.98 3.92 3.76 4 3.79 3 3.53 10
11 2.91 2.84 2.98 5 2.93 3 2.76 3 2.91 2.98 2.90 3 2.81 6 2.71 9
12 3.01 3.00 2.98 1 3.10 3 3.09 3 3.07 3.12 2.50 20 2.98 4 2.92 6
13 3.97 4.06 3.98 2 3.66 10 2.76 32 3.99 3.98 3.95 1 3.92 2 3.79 5
Mean 3.65 3.67 3.47 5 3.39 8 3.12 15 3.68 3.67 3.53 4 3.41 7 3.18 13
SD 0.48 0.48 0.54 9 0.53 9 0.62 14 0.45 0.44 0.55 6 0.49 8 0.57 12
*Inlitres.wFEV1, duringearlyphaseimmediatelyafter allergenchallenge.
zFEV1duringlatephase 3^10 hafter allergenchallenge (meanvalue).
}FEV1duringlatephase 3^10 hafter allergen
challenge (minimumvalue).
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and Fig.1)
There was a signi¢cant decrease in the recovered vo-
lumes of BAL £uid after NO2+allergen (P¼0.03). The
median values of the recovered BW and BAL volumes
after air+allergen exposure were 9ml [ (Interquartile
range (IQR) 7^10ml)] and 105ml (IQR: 101^109ml), re-
spectively. After NO2+allergen exposure, the corre-
sponding ¢gures were 8ml (IQR: 8^10ml) and 93ml
(IQR: 71^105ml).
The cell viability afterNO2+allergenwasunchangedin
BAL, but decreased in the BW after NO2+allergen ex-
posure (75 vs. 47%;P¼0.01, data not shown).
In thebronchoalveolar portion, both the total cell and
macrophage concentrations decreased after NO2+aller-
gen (1420 vs. 1360106L1, P¼0.002; 1235 vs.
1170106 L1, P¼0.03).
The percentage of neutrophils after NO2+allergen ex-
posure increased in BW and BAL (BW11vs.19%, P¼0.05;
BAL1vs. 3%, P¼0.02, median values).
The numbers of eosinophils andmast cells for the two
exposures were not di¡erent.
Solublemediators and albumin (Table 5)
ECP levels increased signi¢cantly in the bronchial por-
tion (BW 3.6 vs. 9mg/l; P¼0.02) after NO2+allergen, but
not in thebronchoalveolar portion.Therewereno signif-
icant di¡erences in IL-8, IL-5, and sICAM-1 levels be-
tween NO2+allergen and air+allergen, neither in BW
nor in BAL. Eotaxin and MPO concentrations in BW
were consistently below detection levels.Therewere no
signi¢cant di¡erences between NO2+allergen and air+-
allergen in albumin levels in lavage £uid (BW; 9 vs. 9;
BAL; 27 vs. 28mgl1, median values), or the ratio albu-
min in lavage £uid/albumin in serum (BW 0.21 vs. 0.21;
BAL 0.63 vs. 0.67, median values).
Correlation between cell counts and ECP, IL-
8, and IL-5
The neutrophil counts were associated with IL-8 levels
(r¼0.59, P¼0.04) in BAL, but not in BW, and with ECP
levels in both BAL and BW (r¼0.77, P¼0.01 and r¼0.60,
P¼0.03, respectively).
The eosinophil counts in BWwere associatedwith IL-8
levels (r=0.68,P¼0.01).The eosinophil counts in BALwere
correlated to the ECP levels (r¼0.57, P¼0.04) and ECP le-
vels correlatedwith IL-5 levels (r¼0.79,P¼0.001) in BAL.
DISCUSSION
The novel ¢nding in this study is that exposure to an am-
bient level of NO2, in the dose tested, enhanced subse-quent allergen-induced in£ammatory reaction in the
bronchi, as demonstrated by enhanced number of re-
cruited neutrophils and levels of ECP. These in£amma-
tory changes were not accompanied by any changes in
pulmonary function or subjective symptoms.
Air pollution is generally recognized as a signi¢cant
factor for asthma aggravation, and NO2 exposure alone
has been linked to increased asthmatic symptoms
and enhanced bronchial responsiveness to both
allergen and nonspeci¢c agents (15).However, the under-
standing of mechanisms for potential synergistic
actions between exposure to air pollution and allergen
is incomplete.
NO2+allergen caused decreased cell viability in BW in
the current study.The cell viability in BW is typically not
a¡ected by allergen challenge (16,17) or NO2 exposure
(7,18). It is theoreticallypossible that the combined expo-
sure to NO2 and allergen leads to an increased release of
cytotoxic substances in the bronchi. Since neither sepa-
rate exposure toNO2 nor allergen havebeen thought to
cause such e¡ect, andnoprevious studyon combined ex-
posure to NO2 and allergen has been reported, these
¢ndings need to be corroborated before an e¡ect of
combined exposure can be determinedwith certainty.
The enhancement of neutrophils in the lower airways
after exposure to NO2 was an important ¢nding in the
current study.There are no published data on the cell re-
sponse in BAL after exposure to NO2 in asthmatic sub-
jects at a comparable time after exposure. However,
NO2 has not earlier been found to increase neutrophils
in BAL in asthmatics immediately after exposure (19).
Normal subjects exposed to NO2 did not show any
change in neutrophil numbers in BW or BAL £uid at a
comparable time (24h after exposure), even though the
concentrationswere six- and15-fold, respectively, higher
than that used in the current study (20,21).The levels of
neutrophils in BWand BAL after air+allergen in the pre-
sent study were similar to those reported in untreated
normal subjects (22) and after NO2+allergen an about
two-fold increasewas seen. Allergen bronchial challenge
per se caused no increase in neutrophils in asthmatics
24h after challenge, although a transient increase of neu-
trophils in BAL £uid could be observed 2^4h after aller-
gen inhalation (9).This indicates that neither exposure to
low levels of NO2 alone nor allergen alone induces a late
airway neutrophilia, which was observed in this study
after combined exposure toNO2 and a low dose of aller-
gen. The potentiating e¡ect of NO2 on the neutrophilic
response was relatively mild in this study. However, we
cannot rule out the possibility that this potentiating ef-
fect of NO2 could be even more pronounced when a
higher allergen dose is chosen.
The quantity of MPO in both BAL and BW did not
reach detectable levels by NO2, suggesting that the neu-
trophils were not signi¢cantly activated, in terms of de-
granulation. An increase in MPO has been associated
TABLE 4. Di¡erential cell counts in BWand BAL
All cells Neutrophils Eosinophils Macrophages Lymphocytes Mastcells
(106 l1) (106 l1) % (106 l1) % (106 l1) % (106 l1) % (106 l1) %
BW
Air/allergen 100 7.0 11 1.8 2 81.0 77 8.3 5 2.0 2
38^220 4.3^26.9 8^19 0.3^8.6 1^9 26.5^177.3 65^84 0.9^17.6 3^10 0.0^3.5 0^4
NO2/allergen 160 24.0 19 1.2 3 104.4 72 7.2 4 1.0 1
90^240 8.3^66.0 8^33 0.0^18.4 0^8 62.6^167.5 55^80 2.0^11.2 2^10 0.0^4.0 0^4
P^ value* n.s. n.s. 0.05 n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s.
BAL
Air/allergen 1420 14.2 1 0.0 0 1235.4 89 120.0 10 3.0 3
1250^1830 0.0^22.5 0^2 0.0^13.5 0^1 1045.6^1683.1 85^95 73.3^211.5 6^14 0.5^4.5 1^5
NO2/allergen 1360 31.0 3 0.0 0 1169.6 88 122.1 8 4.0 4
750^1590 15.1^61.2 1^7 0.0^24.2 0^2 650.5^1498.4 77^92 52.6^158.4 5^14 1.0^6.5 1^7
P^ value* 0.002 0.02 0.02 n.s. n.s. 0.03 n.s. n.s. n.s. n.s. n.s.
Data are given asmedians and interquartile range. n¼13.*Wilcoxon’s pairedrank sumtest; n.s.¼nonsigni¢cant.
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FIG. 1. Neutrophil percentage in lavage £uids after exposure to air+allergen compared to NO2+allergen.The thick horizontal lines
representmedianvalues, boxesrepresent 25th^75thpercentile range.
TABLE 5. Solublemediators in BWand BAL
Albumin(mgl1) ECP(mgl1) IL-5(pgml1) Eotaxin(pgml1) IL-8(pgml1) MPO(mgml1) sICAM-1(ngml1)
BW
Air/allergen 9.00 3.60 0 0 56.80 n.d 18.70
8.00^14.50 0.00^11.50 0.00^9.00 0.00^0.00 21.05^84.65 14.10^26.55
NO2/allergen 9.00 9.00 0 0 54.00 n.d 18.00
7.00^17.00 2.15^22.50 0.00^0.00 0.00^0.00 6.70^112.35 9.65^23.10
P-value n.s. 0.017 n.s. n.s n.s. n.s n.s.
BAL
Air/allergen 27.00 0 0 0 0 n.d 60.30
18.00^35.00 0.00^1.10 0.00^14.20 0.00^0.00 0.00^46.50 44.30^80.00
NO2/Allergen 28.00 2 0 0 27.00 n.d 63.70
17.00^58.00 0.00^3.55 0.00^38.90 0.00^2.55 0.00^95.30 45.00^80.20
P-value n.s n.s n.s. n.s n.s. n.s n.s.
0.091
Data are given as medians and interquartile range; n¼13.*Wilcoxon’s paired rank sum test; n.s.¼nonsigni¢cant; n.d.¼non
detectable.
NO2EFFECTS INASTHMATICSAFTER ALLERGENCHALLENGE 915with an increase of neutrophils in some NO2 studies
(23), but not in others (24). However, since MPO was
not detected after the exposures in this study, the possi-
bility thatmethodological di¡erences exist between our
experimental settings and those cited led to di¡erences
in observations which cannot be excluded.
There is increasing evidence that neutrophils play a
role in asthma and especially in severe persistent asthma
(25), during exacerbations of asthma (26), in status asth-
maticus (27), and in fatal asthma of sudden onset (28).
The fact that NO2 exposure, even at a low concentra-
tion, promotes a neutrophilic type of in£ammation in pa-
tients with allergic asthma might therefore be of
potential clinical importance.
Although the mean levels of IL-8 were not a¡ected in
the current study, a signi¢cant overall correlation was
seen between the number of neutrophils and IL-8 in
BAL. This ¢nding suggests that chemotactic signallingfor further recruitmentof neutrophilswas still occurring
19h after allergen challenge in this NO2^allergen expo-
suremodel.
The levels of ECP after NO2+allergen increased signif-
icantly in BW, and a tendency towards a similar e¡ect
was seen also in BAL.These ¢ndings support a previous
observation that NO2 increased the ECP levels in nasal
lavage £uid after nasal allergen challenge (29). The ECP
level in BW after air+allergen was about one-third of
that seen 24h after challenge with a three-fold greater
allergen dose (16). After NO2+ allergen, the ECP in BW
increased three-fold and reached a level comparable to
that reported after the higher allergen dose. It is note-
worthy that in the current study, the levels of ECP in-
creased although the numbers of eosinophils in BW
were unchanged.One possible explanation of this di¡er-
ence in ECP and eosinophil responsemightbe a selective
e¡ect on degranulation, but not on cell recruitment,
916 RESPIRATORYMEDICINEafter NO2 exposure. Another contributing explanation
is that ECP in BAL £uid origins from both bronchial and
submucosal eosinophils, though their relative contribu-
tion remains unknown. A less likely explanation is that
ECP is produced by other cells, since this possible non-
eosinophil ECP contribution to the overall ECP levels is
not known (30).
NO2 did not a¡ect the asthmatic reaction to inhaled
allergen measured as changes in FEV1 in the current
study, in contrast to what has been seen in several pre-
vious studies (3^5). The NO2 exposure dose has been
the same in two of these studies. However, two factors
di¡er: the individual exposure to NO2 outside the cham-
ber and the dose of allergen. The personal exposure to
NO2 in ambient air (outside the chamber) during the
study day happened to be higher after air than after
NO2 in the current study.This reduced the di¡erence in
NO2 exposure between the NO2 and the control
experiment settings and might thereby have reduced
the probability to detect the e¡ect on lung function re-
lated to NO2 exposure in the chamber. The allergen
doses in the studies in which NO2 a¡ected lung function
after allergen provocation were 10 and 100%, respec-
tively, of PDSRaw 100% (4,5). In the current study, the dose
of allergen was intermediate, 40% of PDSRaw 100%. If
this di¡erence in allergen dose explains the di¡erent
response in pulmonary function, it would imply that
the NO2-induced enhancement of the asthmatic
reaction to inhaled allergen is not linearly related to the
allergen dose.
To conclude, combined exposure to ambient levels of
NO2 and allergen was followed by a late increase in
numbers of neutrophils, which di¡ers from what has
been reported after separate exposure to allergen or
NO2. Moreover, NO2+allergen was followed by
higher ECP levels in the bronchi than after air + allergen.
Present data focus on subclinical in£ammatory reactions
that may occur due to the synergistic action of an
air pollutant and allergen, a situation thatmay frequently
occur in daily life. The clinical impact of the results
needs to be evaluated in future studies to fully
delineate the long-term e¡ect of NO2 exposure in asth-
ma disease.
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